BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

被引：11

作者：

Barbosa Pagnano, Katia Borgia ^{[1
]}

Bendit, Israel ^{[2
]}

Boquimpani, Carla ^{[3
]}

De Souza, Carmino Antonio ^{[1
]}

Miranda, Eliana C. M. ^{[1
]}

Zalcberg, Ilana ^{[4
]}

Larripa, Irene ^{[5
]}

Nardinelli, Luciana ^{[2
]}

Silveira, Rosana Antunes ^{[1
]}

Fogliatto, Laura ^{[6
]}

Spector, Nelson ^{[7
]}

Funke, Vaneuza ^{[8
]}

Pasquini, Ricardo ^{[8
]}

Hungria, Vania ^{[9
]}

Chiattone, Carlos Sergio ^{[9
]}

Clementino, Nelma ^{[10
]}

Conchon, Monika ^{[11
]}

Beatriz Moiraghi, Elena ^{[12
]}

Lopez, Jose Luis ^{[13
]}

Pavlovsky, Carolina ^{[14
]}

Pavlovsky, Miguel A. ^{[14
]}

Cervera, Eduardo E. ^{[15
]}

Antonio Meillon, Luis ^{[16
]}

Simoes, Belinda ^{[17
]}

Hamerschlak, Nelson ^{[18
]}

Magarinos Bozzano, Alicia Helena ^{[19
]}

Mayta, Ernesto ^{[20
]}

Cortes, Jorge ^{[21
]}

Bengio, Raquel M. ^{[5
]}

机构：

[1] Univ Estadual Campinas, UNICAMP, Hemoctr, BR-13083878 Campinas, SP, Brazil

[2] Univ Sao Paulo, Lab Biol Tumoral, Sao Paulo, SP, Brazil

[3] Hemorio, Rio De Janeiro, RJ, Brazil

[4] Inst Nacl Canc, Rio De Janeiro, RJ, Brazil

[5] Acad Nacl Med Buenos Aires, Inst Invest Hematol, Buenos Aires, DF, Argentina

[6] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[7] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil

[8] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil

[9] Santa Casa Sao Paulo, Sao Paulo, SP, Brazil

[10] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil

[11] Hosp Santa Marcelina, Sao Paulo, SP, Brazil

[12] Hosp Ramos Mejia, Buenos Aires, DF, Argentina

[13] Banco Municipal Sangre DC, Caracas, Venezuela

[14] FUNDALEU, Buenos Aires, DF, Argentina

[15] INCAN, Mexico City, DF, Mexico

[16] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[17] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil

[18] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil

[19] Hosp Maciel, Montevideo, Uruguay

[20] Inst Oncol Nacl, Panama City, Panama

[21] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 09期

基金：

巴西圣保罗研究基金会;

关键词：

Chronic myeloid leukemia; BCR-ABL mutations; Imatinib; Resistance; Tyrosine kinase inhibitors; CHRONIC MYELOGENOUS LEUKEMIA; GIMEMA WORKING PARTY; DOMAIN MUTATIONS; EUROPEAN-LEUKEMIANET; IMATINIB RESISTANCE; MANAGEMENT; THERAPY; CML; RECOMMENDATIONS; MESYLATE;

D O I：

10.3109/07357907.2015.1065499

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n=31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p=0.07 and 47% vs. 72%, p=0.03, respectively) and in those with the T315I mutation (p=0.003 and p=0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p=0.01; PFS: 48% vs. 30% p=0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.

引用

页码：451 / 458

页数：8

共 50 条

[21] BCR-ABL TYROSINE KINASE DOMAIN MUTATIONS COMBINATIONS AFFECTS IMATINIB RESISTENCE IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Bintoro, S. U. Y.
Amrita, P. N. A.
Joewarini, E.
Suryohusodo, P.
Soebandiri, S.
NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (04): : 53 - 58
[22] Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Hughes, Timothy
Saglio, Giuseppe
Branford, Susan
Soverini, Simona
Kim, Dong-Wook
Mueller, Martin C.
Martinelli, Giovanni
Cortes, Jorge
Beppu, Lan
Gottardi, Enrico
Kim, Dongho
Erben, Philipp
Shou, Yaping
Haque, Ariful
Gallagher, Neil
Radich, Jerald
Hochhaus, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4204 - 4210
[23] The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels
Wang, Jiaqiao
Hu, June
Jin, Zhiliang
Wan, Huihui
LEUKEMIA RESEARCH, 2016, 47 : 32 - 40
[24] Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib A final report of the MAPTEST study
Lewandowski, Krzysztof
Warzocha, Krzysztof
Hellmann, Andrzej
Skotnicki, Aleksander
Prejzner, Witold
Foryciarz, Kajetana
Sacha, Tomasz
Gniot, Michal
Majewski, Miroslaw
Solarska, Iwona
Nowak, Grazyna
Wasag, Bartosz
Kobelski, Mikolaj
Scibiorski, Cezary
Siemiatkowski, Marek
Lewandowska, Maria
Komarnicki, Mieczyslaw
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (12): : 789 - 794
[25] ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Ernst, Thomas
Hoffmann, Jana
Erben, Philipp
Hanfstein, Benjamin
Leitner, Armin
Hehlmann, Ruediger
Hochhaus, Andreas
Mueller, Martin C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (09): : 1389 - 1393
[26] Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India
Kagita, Sailaja
Uppalapati, Srihari
Jiwatani, Sangeeta
Linga, Vijay Gandhi
Gundeti, Sadasivudu
Nagesh, Narayana
Digumarti, Raghunadharao
TUMOR BIOLOGY, 2014, 35 (07) : 7187 - 7193
[27] BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Leonetti, F.
Stefanachi, A.
Nicolotti, O.
Catto, M.
Pisani, L.
Cellamare, S.
Carotti, A.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (19) : 2943 - 2959
[28] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
Hasanova, Aypara
Asadov, Chingiz
Karimova, Nigar
Shirinova, Aytan
Aliyeva, Gunay
Alimirzoyeva, Zohra
PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
[29] Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia
Strhakova, L.
Bujalkova, M. Gerykova
Hojsikova, I.
Lukackova, R.
Behulova, R.
Mistrik, M.
Repiska, V.
NEOPLASMA, 2011, 58 (06) : 548 - 553
[30] Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation
Shibata, Masaru
Ezoe, Sachiko
Oritani, Kenji
Matsui, Keiko
Tokunaga, Masahiro
Fujita, Natsuko
Saito, Yuri
Takahashi, Takayuki
Hino, Masayuki
Matsumura, Itaru
Kanakura, Yuzuru
LEUKEMIA RESEARCH, 2011, 35 (09) : 1205 - 1211

← 1 2 3 4 5 →